Resolution No. 6/21-2

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT INFLUENZA

The purpose of this resolution is to update the table of inactivated influenza vaccines (IIV) in the VFC program and update the section on contraindications and precautions for IIV and live attenuated influenza vaccine (LAIV).

VFC resolution 6/19-5 is repealed and replaced by the following:

**Inactivated Influenza Vaccine (IIV)**

**Eligible Groups**
*All children aged 6 months through 18 years.*

**Recommended Vaccination Schedule and Intervals**
- 6 months through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations
- 9 through 18 years: 1 dose

The table below lists the currently approved inactivated influenza vaccines in the VFC program, including the age indication for each vaccine.

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Presentation</th>
<th>Age Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afluria (Quadri)</td>
<td>0.25mL pre-filled syringe</td>
<td>6 through 35 months</td>
</tr>
<tr>
<td>Afluria (Quadri)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 36 months</td>
</tr>
<tr>
<td>Afluria (Quadri)</td>
<td>5.0mL multi-dose vial</td>
<td>&gt;=6 months</td>
</tr>
<tr>
<td>Fluarix (Quadri)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Flucelvax (Quadri)*</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;=6 months**</td>
</tr>
<tr>
<td>Flucelvax (Quadri)*</td>
<td>5.0mL multi-dose vial</td>
<td>&gt;=6 months**</td>
</tr>
<tr>
<td>Flulaval (Quadri)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Fluzone (Quadri)</td>
<td>0.5mL pre-filled syringe/sing</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Fluzone (Quadri)</td>
<td>5.0mL multi-dose vial</td>
<td>&gt;= 6 months</td>
</tr>
</tbody>
</table>

Note: The use of brand names is not meant to preclude the use of other comparable licensed vaccines.
*All IIVs and LAIV are egg-based, with the exception of Flucelvax Quadrivalent, which is cell culture-based.

**Updated 10/18/2021 to include an expanded age indication for Flucelvax vaccine effective 10/15/2021.

Minimum Age: 6 months
Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks
Recommended Dosage
Refer to product package inserts available at:
https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states

Contraindications and Precautions
Contraindications:
1. For egg-based IIV: History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after previous dose of any influenza vaccine. However, ACIP makes specific recommendations for the use of influenza vaccine in persons with egg allergy (see Influenza Vaccination of Persons with a History of Egg Allergy, in https://www.cdc.gov/mmwr/volumes/69/rr/rr6908a1.htm).
2. For cell culture-based IIV: history of severe allergic reaction (e.g., anaphylaxis) to cell culture-based IIV or any component of the vaccine.

Precautions:
1. Moderate or severe acute illness with or without fever
2. GBS within 6 weeks following a previous dose of influenza vaccine
3. For cell culture-based IIV only: History of severe allergic reaction to any other influenza vaccine.

Live Attenuated Influenza Vaccine (LAIV)

Eligible Groups
All healthy, non-pregnant children and adolescents (those who do not have an underlying medical condition that predisposes them to influenza complications) aged 2 through 18 years.

Recommended Vaccination Schedule and Intervals
- 2 years through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations
- 9 through 18 years: 1 dose

Minimum Age: 2 years
Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks

Recommended Dosage
Refer to product package insert.

Contraindications and Precautions
Contraindications and precautions can be found at:
https://www.cdc.gov/mmwr/volumes/69/rr/rr6908a1.htm

[If an ACIP recommendation regarding influenza vaccination is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections)
will be replaced with the language in the recommendation and incorporated by reference to the URL.]

Adopted and Effective: June 24, 2021

This document can be found on the CDC website at: https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html